Tech Guru
Long/short equity, biotech, healthcare, tech

Sorrento Has Multiple Shots On Goal, Worth A Closer Look

Sorrento Therapeutics (NASDAQ:SRNE) is a development stage biopharmaceutical company that offers investors a short-term approval/commercialization opportunity in addition to a long-term investment in the company's innovative drug discovery platform.

Sorrento's lead product candidate, Cynviloq, is poised to enter various Phase III clinical trials for a variety of cancer indications including non-small cell lung cancer (NSCLC), metastatic breast cancer ((NYSE:MBC)) and prostate cancer (PC) en route to potential FDA approval via the 505(b)(2) bioequivalence pathway. Cynviloq is a new formulation of the powerful anti-cancer agent Taxol (paclitaxel) and is being developed as a bioequivalent to Celgene's (NASDAQ:CELG) Abraxane.

Abraxane, which is human serum albumin-bound paclitaxel, generated sales of $427 million...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details